foxo4 dri dosing protocol Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes FOXO4-DRI: The Senolytic Peptide That

The 7-day half-life tolerates minor schedule drift

Can peptides help tendon and ligament injuries

doi: 10.1016/j.bbi.2012.08.001, 37 QiuY.NoguchiY.HondaM.NakataH.TamuraY.TanakaS.et al

0.1% (placebo) Steady State: Achieved after 4-5 weeks of weekly dosing Safety: Nausea (68% at 4.5 mg), vomiting (32%), generally mild-moderate and transient Discontinuation: 14% discontinued due to GI adverse events Appetite Effects: Significant reductions in Visual Analogue Scale (VAS) hunger scores Publication: Lau DCW, et al

Absorption Pathway Analysis The nasal spray formulation itself is being studied for its potential to support alternative absorption pathways in research environments